Myocarditis after COVID vaccination is rare but higher in younger males

In a recent study published in the Canadian Medical Association Journal, researchers observed the incidence of myocarditis following messenger ribonucleic acid (mRNA)-based vaccination against coronavirus disease 2019 (COVID-19). Additionally, they compared their estimates with expected rates based on the historical rates assessed before the COVID-19 vaccination rollout in British Columbia (BC), Canada.

Study: Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. Image Credit: Lightspring / ShutterstockStudy: Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. Image Credit: Lightspring / Shutterstock


As of September 2022, nearly 4.5 million people in British Columbia had received a vaccine to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there is hesitancy to receive vaccines, primarily due to the fear of adverse effects. The prelicensing studies had not suggested any risk of post-vaccination myocarditis. However, post-marketing studies linked myocarditis to SARS-CoV-2 mRNA vaccines, among other adverse events after immunization, raising concerns regarding their safety, specifically in the younger population.

Evidence from case reports and case series suggests higher rates of myocarditis among young adults after the mRNA-1273 compared with the BNT162b2 vaccine. Unfortunately, there is a shortage of data concerning the rate of myocarditis after the third vaccine, which is crucial for future booster strategies against COVID-19.

About the study

In the present study, researchers recruited individuals over 12 years who received an mRNA SARS-CoV-2 vaccination (BNT162b2 or mRNA-1273) per the BC Provincial Immunization Registry between December 15, 2020, and March 10, 2022.

The BC Provincial Immunization Registry is a surveillance platform that compiles population health administrative data, including COVID-19-related laboratory tests, vaccinations, case surveillance, and hospital and intensive care unit [ICU] admissions. It also maintains a record of emergency department (ED) visits, physician billings, pharmaceutical dispensations, laboratory tests, chronic diseases, and deaths dating back to 2008.

The team estimated background (expected) rates of myocarditis incidence using BC COVID-19 cohort data on hospital admissions and ED visits from 2015 to 2020. Since these rates increased over time, they used the rates from 2019 for the observed-to-expected analyses, which compare the number of cases reported to the number of cases expected under the null hypothesis. The null hypothesis implies no association between the intervention and the disease.

Study findings

The observed rates of myocarditis-related hospital admissions or ED visits after SARS-CoV-2 mRNA vaccination were higher than expected rates. In addition, the researchers noted the highest rates of myocarditis after the second vaccination among males aged 18 to 29 years (younger population). Though overall rates of myocarditis per 100000 doses were very low for both mRNA vaccines, the rates were about four-fold higher with the mRNA-1273 vaccine than the BNT162b2 vaccine. Intriguingly, the observed myocarditis rates were lower after the third vaccination. Moreover, most cases were mild, with short durations of hospital admission and quick resolution. Overall, the study results showed the overall safety of the mRNA vaccines.

The researchers noted the highest absolute rates for myocarditis among 12–17-year-old men who received the BNT162b2 vaccine. The observed-to-expected ratios of myocarditis among these men were also the highest. The mRNA-1273 vaccine was not administered to those aged between 12 and 17. Also, no previous studies reported this comparison; they combined age groups (e.g., 16–29 or 12–39 years) or analyzed rates only for BNT162b2 recipients aged between 12 to 17 years. Although the current study analyses suggested a higher risk of myocarditis following mRNA-1273 than the BNT162b2 vaccine in younger individuals, the 12 to 17-year age group needs additional investigation.

There is growing evidence of a potential causal relationship between SARS-CoV-2 mRNA vaccines and myocarditis. However, risk-benefit assessments appear skewed towards the benefits of mRNA SARS-CoV-2 vaccines. As per a recent US analysis, one million-second dose of mRNA SARS-CoV-2 vaccine saved 560 hospital admissions, 138 ICU admissions, 11 000 cases, and six COVID-19-related deaths, with only 39 to 47 expected cases of myocarditis. Likewise, a study by Patone et al. found an extra 10 myocarditis events per million patients in the 28 days after they received the second dose of the mRNA-1273 vaccine. On the contrary, extra 40 myocarditis events occurred in one million patients in the same time frame after testing SARS-CoV-2-positive.


The researchers observed higher incidence rates of myocarditis after mRNA vaccination than expected, but absolute rates remained low. Although the observed rates were higher than historical background rates, SARS-CoV-2 vaccination reduced infection severity, hospital admissions, and deaths. Indeed, mRNA COVID-19 vaccination benefits outweigh the risk of developing myocarditis. Younger people aged 18 to 29 were among the worst hit by myocarditis. Thus, the preferred strategy should be their continued vaccination, albeit with monitoring of adverse event(s).

Journal reference:
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2022, November 22). Myocarditis after COVID vaccination is rare but higher in younger males. News-Medical. Retrieved on June 25, 2024 from

  • MLA

    Mathur, Neha. "Myocarditis after COVID vaccination is rare but higher in younger males". News-Medical. 25 June 2024. <>.

  • Chicago

    Mathur, Neha. "Myocarditis after COVID vaccination is rare but higher in younger males". News-Medical. (accessed June 25, 2024).

  • Harvard

    Mathur, Neha. 2022. Myocarditis after COVID vaccination is rare but higher in younger males. News-Medical, viewed 25 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How COVID-19 disrupts social and temporal perception